Patent · US Expired

Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands

US5840888A · kind A · utility

51Cited by
1References
1Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 6, 1995
Grant dateNov 24, 1998
Priority date
Expiry dateJun 6, 2015

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D487/04
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

##STR1## The present invention encompasses compounds of formula (I), and the pharmaceutical acceptable non-toxic salts thereof wherein: where X represents hydrogen or lower alkyl; W represents an aryl group unsubstituted or substituted with various organic and inorganic substituents; (a) represents (b); (c); (d) or (e) or (a) represents (f), where A, B, C, D, and E represent carbon or nitrogen substituted with hydrogen or various organic and inorganic substituents; and n is 0, 1, or 2; Y, R.sub.3, R.sub.4, R.sub.12, and R.sub.13 are various organic and inorganic substituents. These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs thereof and are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overdose with benzodiazepine drugs, and enhancement of memory.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.